GlassScriptPhysician profile
Gnana Sunderam
NPI 1164446761
$32,942.99
in general payments reported to CMS, 2019-2025
15 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $10K · 2021: $8,569 · 2022: $675 · 2023: $481 · 2024: $139 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $790.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $19,730.10 | 2019-2022 | |
| Glaxosmithkline, LLC. | $11,172.40 | 2019-2025 | Nucala, Trelegy Ellipta |
| Dexcom, INC. | $1,193.45 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $323.74 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $162.93 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.77 | 2023 | |
| Embecta Corp. | $62.70 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Lilly USA, LLC | $56.40 | 2020-2021 | |
| Allergan, INC. | $41.37 | 2020-2021 | |
| Amgen INC. | $29.65 | 2023-2024 | Repatha |
| Becton, Dickinson and Company | $29.14 | 2020-2021 | |
| Nabriva Therapeutics, Plc | $25.94 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $16.99 | 2025 | Nuplazid |
| Novo Nordisk INC | $15.30 | 2020 | |
| Xeris Pharmaceuticals, INC. | $15.11 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gnana Sunderam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.